Icotinib

Lung Neoplasm

Fuda Cancer Hospital, GuangzhouSmall moleculePhase 4 / ApprovedDormant

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 61/ 100
Competitive Position: 73/ 100

Competitive context

52 Active assets in the Lung Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Carboplatin Nanfang Hospital, Southern Medical University	Phase 4	BB
Nivolumab Hospital Israelita Albert Einstein	Phase 2	BB
Belagenpumatucel-L (Sk-Lu-1) NovaRx Corporation	Phase 3	BB
Rivoceranib Fuzhou General Hospital	Phase 3	BB
Cyclophosphamide Pfizer	Phase 3	BB

View all 47 →

Same molecule, other indications

Icotinib is also rated in:

non-small cell lung carcinomaActive

BBB

Indicative · Phase 4

74 / 100

adenocarcinomaDormant

BB

Indicative · Phase 4

70 / 100

metastatic malignant neoplasm in the brainDormant

BB

Indicative · Phase 3

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.